From the Department of Surgery, Beth Israel Deaconess Medical Center.
Boston University School of Medicine.
Ann Plast Surg. 2023 Nov 1;91(5):534-539. doi: 10.1097/SAP.0000000000003706. Epub 2023 Sep 23.
BACKGROUND: Gender-affirming surgery is a quickly expanding field. However, it is facing a shortage of specialized surgeons for a population exceeding 1.4 million individuals. Many studies comparing outcomes between cisgender and transgender patients fail to describe the technical differences of the operation. Breast augmentation in the transgender female patient involves important anatomical, technical, and clinical features that differ from the cisgender female. In this study, we aimed to describe and compare these characteristics between these 2 groups to better inform the new generation of gender-affirming surgeons. METHODS: A retrospective cohort study of patients who underwent primary breast augmentation between 2009 and 2019 at a specialized tertiary center for transgender care was performed. Mastopexy, secondary augmentation, and reconstructive procedures were excluded. Demographic, operative, and clinical data were collected from medical records. All patients had a minimum of 1 year of follow-up after the initial surgery. Bivariate analysis was performed. RESULTS: A total of 250 cisgender females and 153 transgender females were included. The transgender group showed higher rates of smoking ( P < 0.0001), immunosuppression ( P < 0.0001), obesity ( P < 0.0001), mental health disorders ( P < 0.0001), and hypertension ( P = 0.002). Median base width ( P < 0.0001), sternal notch to nipple distance ( P < 0.0001), and implant size (500 mL [interquartile range, 425-600 mL] vs 350 mL [interquartile range, 325-385 mL]; P < 0.0001) were larger in transgender patients. Transgender patients also demonstrated a stronger correlation between implant size and body surface area ( r = 0.71, P < 0.0001). Readmission, reoperation, and complication rates were similar between the groups; however, transgender females had a higher incidence of surgical site infections (3.9% vs 0.4%, P < 0.013). Capsular contracture was the most common complication and indication for reoperation in both groups. CONCLUSIONS: There are important anatomical, clinical, and technical differences between reconstructive gender-affirming breast augmentation in transgender female patients and cosmetic breast augmentation in the cisgender female. The gender-affirming surgeon must know these differences to provide the best quality of care and help patients achieve better congruence between their gender identity and body image.
背景:性别肯定手术是一个迅速发展的领域。然而,面对超过 140 万人口,专门的外科医生却短缺。许多比较顺性别和跨性别患者结果的研究未能描述手术的技术差异。跨性别女性的乳房增大涉及到与顺性别女性不同的重要解剖学、技术和临床特征。在这项研究中,我们旨在描述和比较这两组之间的这些特征,以便为新一代性别肯定外科医生提供更好的信息。
方法:对 2009 年至 2019 年在一家专门的跨性别护理三级中心接受原发性乳房增大的患者进行了回顾性队列研究。排除了乳房下垂术、二次增大和重建手术。从病历中收集人口统计学、手术和临床数据。所有患者在初次手术后至少有 1 年的随访。进行了双变量分析。
结果:共纳入 250 名顺性别女性和 153 名跨性别女性。跨性别组的吸烟率(P < 0.0001)、免疫抑制(P < 0.0001)、肥胖(P < 0.0001)、精神健康障碍(P < 0.0001)和高血压(P = 0.002)发生率更高。跨性别患者的基底宽度中位数(P < 0.0001)、胸骨切迹至乳头距离中位数(P < 0.0001)和植入物大小中位数(500 mL [四分位距,425-600 mL] 比 350 mL [四分位距,325-385 mL];P < 0.0001)均较大。跨性别患者的植入物大小与体表面积之间也显示出更强的相关性(r = 0.71,P < 0.0001)。两组患者的再入院率、再次手术率和并发症发生率相似;然而,跨性别女性的手术部位感染发生率更高(3.9%比 0.4%,P < 0.013)。包膜挛缩是两组中最常见的并发症和再次手术指征。
结论:在跨性别女性的重建性性别肯定乳房增大和顺性别女性的美容乳房增大之间存在重要的解剖学、临床和技术差异。性别肯定外科医生必须了解这些差异,以便提供最佳的护理质量,并帮助患者实现其性别认同和身体形象之间更好的一致性。
J Plast Reconstr Aesthet Surg. 2021-11
Plast Reconstr Surg Glob Open. 2019-10-29
Aesthetic Plast Surg. 2021-8
Plast Reconstr Surg. 2024-6-1
Plast Reconstr Surg Glob Open. 2025-8-13
Plast Reconstr Surg Glob Open. 2024-8-1